Cargando…

Effects of oral isotretinoin therapy on the nasal cavities()()

INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints...

Descripción completa

Detalles Bibliográficos
Autores principales: Tasli, Hamdi, Yurekli, Aslan, Gokgoz, Mert Cemal, Karakoc, Omer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422455/
https://www.ncbi.nlm.nih.gov/pubmed/30472003
http://dx.doi.org/10.1016/j.bjorl.2018.10.004
_version_ 1784777815972904960
author Tasli, Hamdi
Yurekli, Aslan
Gokgoz, Mert Cemal
Karakoc, Omer
author_facet Tasli, Hamdi
Yurekli, Aslan
Gokgoz, Mert Cemal
Karakoc, Omer
author_sort Tasli, Hamdi
collection PubMed
description INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints of patients with severe acne who received oral isotretinoin therapy. METHODS: Fifty-four subjects were enrolled in the study. All the subjects were assessed with subjective (NOSE and VAS questionnaires) and objective (rhinomanometry and saccharine) tests to determine the severity of their nasal complaints. RESULTS: The mean severity scores (min: 0; max: 100) for nasal dryness/crusting and epistaxis were 0.47 ± 1.48 (0–5); 0.35 ± 1.30 (0–5) at admission, 3.57 ± 4.45 (0–10); 2.26 ± 4.71 (0–20) at the first month, and 4.28 ± 6 (0–20); 2.26 ± 4.71 (0–20) at the third month of the treatment respectively. Total nasal resistance of 0.195 ± 0.079 (0.12–0.56) Pa/cm(3)/s at admission, 0.21 ± 0.084 (0.12–0.54) Pa/cm(3)/s at the first month, and 0.216 ± 0.081 (0.14–0.54) Pa/cm(3)/s at the third month. CONCLUSION: Oral isotretinoin therapy can cause the complaint of nasal obstruction. In addition, nasal complaints, such as dryness/crusting and epistaxis, significantly increase in patients during the therapy schedule.
format Online
Article
Text
id pubmed-9422455
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94224552022-08-31 Effects of oral isotretinoin therapy on the nasal cavities()() Tasli, Hamdi Yurekli, Aslan Gokgoz, Mert Cemal Karakoc, Omer Braz J Otorhinolaryngol Original Article INTRODUCTION: Isotretinoin (13 cis-retinoic acid) is the most effective treatment for acne vulgaris and is the only treatment option that can provide either remission or a permanent cure. OBJECTIVE: The aim of this study was to use both subjective and objective methods to assess the nasal complaints of patients with severe acne who received oral isotretinoin therapy. METHODS: Fifty-four subjects were enrolled in the study. All the subjects were assessed with subjective (NOSE and VAS questionnaires) and objective (rhinomanometry and saccharine) tests to determine the severity of their nasal complaints. RESULTS: The mean severity scores (min: 0; max: 100) for nasal dryness/crusting and epistaxis were 0.47 ± 1.48 (0–5); 0.35 ± 1.30 (0–5) at admission, 3.57 ± 4.45 (0–10); 2.26 ± 4.71 (0–20) at the first month, and 4.28 ± 6 (0–20); 2.26 ± 4.71 (0–20) at the third month of the treatment respectively. Total nasal resistance of 0.195 ± 0.079 (0.12–0.56) Pa/cm(3)/s at admission, 0.21 ± 0.084 (0.12–0.54) Pa/cm(3)/s at the first month, and 0.216 ± 0.081 (0.14–0.54) Pa/cm(3)/s at the third month. CONCLUSION: Oral isotretinoin therapy can cause the complaint of nasal obstruction. In addition, nasal complaints, such as dryness/crusting and epistaxis, significantly increase in patients during the therapy schedule. Elsevier 2018-11-12 /pmc/articles/PMC9422455/ /pubmed/30472003 http://dx.doi.org/10.1016/j.bjorl.2018.10.004 Text en © 2018 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Tasli, Hamdi
Yurekli, Aslan
Gokgoz, Mert Cemal
Karakoc, Omer
Effects of oral isotretinoin therapy on the nasal cavities()()
title Effects of oral isotretinoin therapy on the nasal cavities()()
title_full Effects of oral isotretinoin therapy on the nasal cavities()()
title_fullStr Effects of oral isotretinoin therapy on the nasal cavities()()
title_full_unstemmed Effects of oral isotretinoin therapy on the nasal cavities()()
title_short Effects of oral isotretinoin therapy on the nasal cavities()()
title_sort effects of oral isotretinoin therapy on the nasal cavities()()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422455/
https://www.ncbi.nlm.nih.gov/pubmed/30472003
http://dx.doi.org/10.1016/j.bjorl.2018.10.004
work_keys_str_mv AT taslihamdi effectsoforalisotretinointherapyonthenasalcavities
AT yurekliaslan effectsoforalisotretinointherapyonthenasalcavities
AT gokgozmertcemal effectsoforalisotretinointherapyonthenasalcavities
AT karakocomer effectsoforalisotretinointherapyonthenasalcavities